Update shared on04 Sep 2025
With both the future P/E ratio and consensus revenue growth forecasts remaining essentially unchanged, analysts have maintained DSM-Firmenich’s fair value estimate at €117.70.
What's in the News
- DSM-Firmenich launched Lacteol® diarrhEase™ Kids, a top pediatrician-recommended postbiotic for children as young as six months, in the U.S. market.
- The product leverages stabilized Lactobacillus LB, is drug-free, and targets pediatric digestive issues, supported by 40 peer-reviewed studies and 18 clinical trials.
- The company completed a share buyback of 4,580,734 shares (1.73% of outstanding shares) for €432 million.
Valuation Changes
Summary of Valuation Changes for DSM-Firmenich
- The Consensus Analyst Price Target remained effectively unchanged, at €117.70.
- The Future P/E for DSM-Firmenich remained effectively unchanged, moving only marginally from 33.38x to 33.64x.
- The Consensus Revenue Growth forecasts for DSM-Firmenich remained effectively unchanged, at 2.9% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.